Aktiesnakken — Juni 2013
-
396
-
jeg lurer stadig
-
Godt nyt fra Veloxis-studie
Veloxis offentliggør positive resultater for hovedaktiv, lægemiddelkandidaten LCP-Tacro.
(medwatch.dk)
-
Veloxis Announces Positive Results of 3002 Study: LCP-TacroTM Meets Primary Efficacy and Safety Endpoints in de Novo Kidney Transplant Patients
LCP-TacroTM, once-daily, demonstrated non-inferiority to Prograf
, twice-daily, based on the composite endpoint of treatment failure at one year (LCP-TacroTM 18.3%, Prograf 19.6%)
Treatment failure rates through the first three months after transplant were 10.4% for LCP-TacroTM and 14.2% for Prograf
Similar incidence of adverse events and impact -
Veloxis kommer med positive phase III
-
YES YES YES YES YES
-
Og det mest vigtige. Dødeligheden var 8 tilfælde i begge studier dvs. ingen forskel i armene
-
Alle endpoints er Tacro bedre end Prograf ! Samtlige
-
Det var det eneste jeg var bange for. i det første phase III havde tacro højere dødelighed. Her er de ens hvilket er sindsygt positivt
-
godt for veloxis folket. tillykke!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind